Drug and Therapeutics Bulletin 1995;33:47-48; doi:10.1136/dtb.1995.33647
Copyright © 1995 by the BMJ Publishing Group Ltd.
Selective serotonin reuptake inhibitors in obsessive-compulsive disorder
Relevant BNF section: 4.3.3
Since we reviewed the selective serotonin reuptake inhibitor (SSRI) antidepressants two years ago1 two of them, fluoxetine (Prozac - Dista) and fluvoxamine (Faverin - Duphar), have also been licensed for the treatment of patients with obsessive-compulsive disorder. How do these and the other SSRIs available in the UK - paroxetine (Seroxat - SmithKline Beecham) and sertraline (Lustral - Invicta/Pfizer) - compare with clomipramine, a standard drug treatment for this disorder?2,3
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Infections
-
Malignant disease and immunosuppression
-
Musculoskeletal and joint disorders
-
Psychiatry
-
Neurology (drugs and medicines)
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
